Canadian biopharmaceutical firm Bioniche Life Sciences Inc. has entered a urology drug deal with U.S-based Endo Pharmaceuticals worth up to $130 million, essentially eliminating the company's cash burn for its bladder cancer program. (BioWorld Today)

Catalyst Biosciences has secured another big deal focused on its Alterase drug discovery engine, this time partnering with MedImmune, the global biologics unit of AstraZeneca plc, to develop drug candidates against two targets, one of which will address inflammatory and autoimmune diseases. (BioWorld Today)

Ikaria Holdings Inc. has entered a deal worth a potential $282.5 million with Jerusalem-based BioLineRx Ltd. to license a cardiac remodeling product. (BioWorld Today)

Johnson & Johnson plans to make a whopping $1.5 billion investment in Elan Corp. plc in exchange for a stake in Dublin-based Elan, in a deal that will transfer key Alzheimer's programs, including Phase III bapineuzumab, to the U.S. drugmaker. (BioWorld Today)